{"product_id":"exelixis-marketing-mix","title":"Exelixis Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Exelixis aligns its product portfolio, pricing architecture, distribution channels, and promotional tactics to compete in oncology markets. This concise 4Ps snapshot highlights strategic levers and market positioning. For a deep, editable analysis with data, examples, and ready-to-use slides, get the full 4P’s Marketing Mix report now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology therapeutics portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis develops targeted therapies and immuno-oncology combinations addressing unmet cancer needs, with flagship small-molecule TKI cabozantinib approved across RCC, HCC and differentiated thyroid cancer (three core solid-tumor indications).\u003c\/p\u003e\n\u003cp\u003eCabozantinib demonstrated overall survival benefit in METEOR (HR 0.66) and programs prioritize clinical benefit, tolerability and line-of-therapy relevance.\u003c\/p\u003e\n\u003cp\u003eLifecycle management focuses on label expansions, new formulations and IO combo regimens to extend utility and market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabozantinib franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCABOMETYX and COMETRIQ anchor Exelixis’ cabozantinib franchise with approvals in renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. Ongoing pivotal studies such as COSMIC-312 and other IO-combination trials seek label expansions and optimized sequencing with immune-oncology backbones. Differentiation emphasizes multi-kinase inhibition and emerging real-world effectiveness and safety data. Physician education focuses on dosing strategies, adverse-event management and quality-of-life outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNext-gen TKIs, ADCs, and cell-cycle inhibitors in Exelixis pipeline focus on resistant disease and novel pathways, with rapid proof-of-concept readouts often targeted within ~12 months to inform go\/no-go and partnering choices.\u003c\/p\u003e\n\u003cp\u003ePortfolio design balances risk via diversified mechanisms across small molecules and biologics, while companion biomarker and translational research refine patient selection to raise response rates and lower development attrition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and provider support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient and provider support for Exelixis therapies combines access programs, reimbursement navigation, and co-pay assistance to ease adoption; nurse and pharmacy hotlines support initiation and adherence, while educational kits guide AE monitoring and dose adjustments and multilingual resources extend reach across diverse populations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess programs streamline prior authorizations\u003c\/li\u003e\n\u003cli\u003eReimbursement support reduces payer barriers\u003c\/li\u003e\n\u003cli\u003eCo-pay assistance lowers out‑of‑pocket costs\u003c\/li\u003e\n\u003cli\u003eNurse\/pharmacy hotlines aid adherence\u003c\/li\u003e\n\u003cli\u003eEducational kits for AE monitoring and dose changes\u003c\/li\u003e\n\u003cli\u003eMultilingual materials increase equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality, safety, and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExelixis enforces rigorous manufacturing and pharmacovigilance to uphold product reliability, supporting 2024 reported product revenue of $1.07 billion and fewer than 0.5% lot failures reported company-wide.\u003c\/p\u003e\n\u003cp\u003eOngoing post-marketing surveillance drives labeling updates and risk mitigation actions; 2024 safety communications led to two label revisions for cabozantinib.\u003c\/p\u003e\n\u003cp\u003eQuality systems align with global regulators (FDA, EMA) and continuous improvement initiatives cut supply and safety incidents, lowering supply interruptions by ~30% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing robustness\u003c\/li\u003e\n\u003cli\u003eActive pharmacovigilance\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment\u003c\/li\u003e\n\u003cli\u003eContinuous improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabozantinib: \u003cstrong\u003e$1.07B\u003c\/strong\u003e 2024 rev, METEOR OS HR \u003cstrong\u003e0.66\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis’ product strategy centers on cabozantinib across RCC, HCC and DTC with 2024 product revenue $1.07B and METEOR OS HR 0.66.\u003c\/p\u003e\n\u003cp\u003eLifecycle moves: label expansions, IO combos (COSMIC-312), new formulations and real‑world safety‑driven label changes (2 in 2024).\u003c\/p\u003e\n\u003cp\u003eManufacturing lot failures \u0026lt;0.5%, supply interruptions down ~30% YoY; patient support and reimbursement programs drive uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product revenue\u003c\/td\u003e\n\u003ctd\u003e$1.07B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMETEOR OS\u003c\/td\u003e\n\u003ctd\u003eHR 0.66\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabel revisions 2024\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot failure rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply interruptions YoY\u003c\/td\u003e\n\u003ctd\u003e-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Exelixis’s Product, Price, Place, and Promotion strategies, grounded in its oncology portfolio, pricing dynamics, distribution partnerships, and targeted promotional tactics. Ideal for managers or consultants needing a ready-to-use, evidence-based marketing positioning brief adaptable for reports, presentations, or strategic benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Exelixis's 4Ps in a clean, structured one-pager that relieves stakeholder confusion and accelerates alignment for leadership meetings or rapid go-to-market decisions; easily customizable and plug-and-play for decks, comparisons, or workshop use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty distribution channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis supplies oncology clinics and hospitals via specialty distributors and pharmacies, routing oral and injectable therapies through controlled handling networks. Cold-chain and handling protocols (maintaining required temperature ranges and chain-of-custody tracking) preserve product integrity. Inventory visibility platforms enable timely refills to sustain therapy continuity. HUB services provide 24\/7 coordination of shipments and benefits verification for patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and cancer center access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional formulary placement drives in-hospital initiation of Exelixis therapies, supported by infusion centers and 1,500+ outpatient oncology clinics that facilitate combination regimens; pathways integration streamlines physician ordering while educator teams onboard pharmacy and nursing staff—Exelixis reported roughly $1.2 billion in 2024 net product revenue, underscoring hospital channel importance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal partnerships for ex-US\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegional partners manage registration, distribution and promotion outside the U.S.; for example Ipsen holds ex-US rights for cabozantinib and markets in 100+ countries. Local affiliates tailor market access to fragmented payer structures and negotiate country-specific reimbursement. Supply planning aligns production with tenders and country demand to avoid stockouts. Medical affairs coordinates global scientific communication to ensure consistency across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical trial networks expand early access and generate real-world evidence that guides Exelixis launch sequencing and channel allocation; efficient site activation shortens enrollment timelines across tumor cohorts, improving time-to-readout. Decentralized tools broaden geographic reach and, per IQVIA 2023, can boost patient retention by about 20%, enhancing dataset completeness for commercial planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eNetworks drive early access + RWE for launch sequencing\u003c\/li\u003e\n\u003cli\u003eFaster site activation accelerates cohort enrollment\u003c\/li\u003e\n\u003cli\u003eDecentralized tools increase reach; ~20% retention gain (IQVIA 2023)\u003c\/li\u003e\n\u003cli\u003eTrial data informs channel allocation and market timing\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital ordering and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital ordering and support enable provider portals for e-prescribing, prior authorization initiation, and status tracking, leveraging widespread EHR adoption (96% of US hospitals had certified EHRs by 2022) and e-prescribing penetration above 70% in ambulatory care by 2023. Integrated EHR workflows simplify onboarding and analytics surface coverage gaps and regional availability in near real-time.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ee-prescribing: \u0026gt;70% ambulatory adoption (2023)\u003c\/li\u003e\n\u003cli\u003eEHR reach: 96% hospitals certified (2022)\u003c\/li\u003e\n\u003cli\u003eFunctions: prior auth, status tracking, inventory updates\u003c\/li\u003e\n\u003cli\u003eValue: analytics flag coverage and regional shortages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital channel drives oncology starts: \u003cstrong\u003e$1.2B\u003c\/strong\u003e revenue, \u003cstrong\u003e1,500+\u003c\/strong\u003e clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis distributes oncology therapies via specialty distributors, hospitals and 1,500+ outpatient clinics, with cold-chain controls and HUB services supporting 24\/7 shipment coordination. Institutional formulary placement and trials drive in-hospital starts; 2024 net product revenue ≈ $1.2B underscores hospital channel importance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient clinics\u003c\/td\u003e\n\u003ctd\u003e1,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net revenue\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIQVIA trial retention (2023)\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHR hospital reach (2022)\u003c\/td\u003e\n\u003ctd\u003e96%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmbulatory e-prescribe (2023)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eExelixis 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Exelixis 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete and ready to use. This is not a sample or demo; the editable, high-quality document available for download after checkout is identical to what you see. Buy with full confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164697407865,"sku":"exelixis-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/exelixis-marketing-mix.png?v=1762738781","url":"https:\/\/portersfiveforce.com\/products\/exelixis-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}